|
Effect of the application of recombinant human erythropoietin on retinopathy of prematurity.
HE Jin-shui,HUANG Zhong-ling,YANG Hong,WENG Kai-zhi,ZHU Shao-bo,LUO Tian-chang,ZHANG Bao-xian,CAI Hui-fang,ZHOU Ji-guang.
2009, 24(05):
375-378 .
Objective To evaluate the effect of the application of recombinant human erythropoietin (rhu-EPO) on retinopathy of prematurity(ROP). Methods All the clinical data of in-patient infants whose body weights were no more than 1500g during the period from March 2005 to June 2008 were reviewed. The group treated with rhu-EPO had 94 infants. Control group of 65 infants were not treated with rhu-EPO. Perform examination of fundus to the infants who were postnatal 6 weeks or whose correctal gestational ages were 35 weeks. Diagnosis and staging of ROP were established according to the international guidelines, and statistical analysis was done on several correlation factors at the same time. Results Treatment group had higher incidence rate of serious ROP than control group (P < 0.05).Analysis of single factor showed no-less-than 10 doses of rhu-EPO treatment had higher risk of serious ROP than less than 10 doses of rhu-EPO treatment (r = 6.429,P < 0.001). The beginning therapy time no less than fourteen days had higher risk of serious ROP than that of less than fourteen days(r = 46.000,P < 0.001). Logistic analysis of multiple factors displayed that no less than 10 doses of rhu-EPO treatment had higher risk of serious ROP(r = 9.348,P < 0.001).Conclusion The application of recombinant Human Erythropoietin (rhu-EPO) is an independent risk factor of retinopathy of prematurity.
|